title: Impact of androgen deprivation on physical well-being in patients with prostate cancer: analysis from the CaPSURE (Cancer of the Prostate Strategic Urologic Research Endeavor) registry.
abstract: BACKGROUND
  As androgen deprivation therapy (ADT) becomes a standard of treatment for men with recurrent or metastatic prostate cancer, evaluation of adverse effects associated with this treatment is needed. In this study, the authors evaluated the effect of ADT administered as monotherapy and in combination with local treatment on physical well-being in a longitudinal sample of men with prostate cancer.
  
  
  METHODS
  Exposure to ADT was defined by 3 groups: local (local treatment only), combination (local treatment with adjuvant and/or neoadjuvant ADT), and primary ADT. Associations between exposure to ADT and physical well-being measured by self-reported health-related quality of life outcomes over time were evaluated by repeated measures analysis using mixed modeling. Estimates adjusted for various clinical and demographic variables are reported.
  
  
  RESULTS
  A total of 2922 men, who completed both pretreatment and follow-up health-related quality of life assessment, were identified from the CaPSURE (Cancer of the Prostate Strategic Urologic Research Endeavor) registry. During 24 months of follow-up, exposure to ADT was associated with worse physical well-being compared with local treatment at all time points (P < .001). Being exposed to ADT as primary therapy was associated with more severe declines compared with combination therapy.
  
  
  CONCLUSIONS
  The potential consequence of decline in physical well-being in patients exposed to ADT has to be included in treatment decision making.
authors.affiliation: Department of Urology, University of California, San Francisco, San Francisco, California, USA. nsadetsky@urology.ucsf.edu
authors.forename: Natalia
authors.initials: N
authors.lastname: Sadetsky
authors.forename: Kirsten
authors.initials: K
authors.lastname: Greene
authors.forename: Matthew R
authors.initials: MR
authors.lastname: Cooperberg
authors.forename: Alan
authors.initials: A
authors.lastname: Hubbard
authors.forename: Peter R
authors.initials: PR
authors.lastname: Carroll
authors.forename: William
authors.initials: W
authors.lastname: Satariano
mesh_terms: D000230:Adenocarcinoma / Q000628:therapy*; D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D015331:Cohort Studies; D003131:Combined Modality Therapy; D003657:Decision Making; D005500:Follow-Up Studies; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D009376:Neoplasms, Hormone-Dependent / Q000628:therapy*; D009919:Orchiectomy; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000628:therapy*; D011788:Quality of Life; D012042:Registries; D015996:Survival Rate
chemical_list: D000726:Androgen Antagonists